questionsmedicales.fr
Facteurs biologiques
Protéines et peptides de signalisation intercellulaire
Cytokines
Chimiokines
Chimiokines CC
Protéines chimioattractives monocytaires
Chimiokine CCL2
Chimiokine CCL2 : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Chimiokines
CCL2
Tests de laboratoire
Inflammation
CCL2
Protéines C-réactives
Biomarqueurs
Maladies auto-immunes
CCL2
Maladies cardiovasculaires
Inflammation
CCL2
Liquide céphalorachidien
Inflammation
CCL2
Symptômes
5
Symptômes
Inflammation
CCL2
Sclérose en plaques
Symptômes neurologiques
CCL2
Système immunitaire
Monocytes
CCL2
Douleur
Inflammation
CCL2
Prévention
5
Mode de vie sain
CCL2
Prévention
Alimentation
Antioxydants
CCL2
Sommeil
Inflammation
CCL2
Traitements
5
Inhibiteurs
Maladies inflammatoires
CCL2
Thérapies anticancéreuses
CCL2
Inflammation
Anti-inflammatoires
CCL2
Inflammation
Plantes médicinales
CCL2
Traitements naturels
Corticostéroïdes
CCL2
Inflammation
Complications
5
Complications
Maladies cardiovasculaires
CCL2
Maladies neurodégénératives
Alzheimer
CCL2
Diabète
Inflammation
CCL2
Infections
Inflammation
CCL2
Troubles auto-immuns
Polyarthrite
CCL2
Facteurs de risque
5
Infections chroniques
CCL2
Inflammation
Régime alimentaire
Graisses saturées
CCL2
Manque d'exercice
Inflammation
CCL2
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Chimiokine CCL2 : Questions médicales les plus fréquentes",
"headline": "Chimiokine CCL2 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Chimiokine CCL2 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-26",
"dateModified": "2025-02-20",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Chimiokine CCL2"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protéines chimioattractives monocytaires",
"url": "https://questionsmedicales.fr/mesh/D018945",
"about": {
"@type": "MedicalCondition",
"name": "Protéines chimioattractives monocytaires",
"code": {
"@type": "MedicalCode",
"code": "D018945",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.374.200.110.990"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Chimiokine CCL2",
"alternateName": "Chemokine CCL2",
"code": {
"@type": "MedicalCode",
"code": "D018932",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Nidhi Joshi",
"url": "https://questionsmedicales.fr/author/Nidhi%20Joshi",
"affiliation": {
"@type": "Organization",
"name": "Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee 247667, Uttarakhand, India."
}
},
{
"@type": "Person",
"name": "Krishna Mohan Poluri",
"url": "https://questionsmedicales.fr/author/Krishna%20Mohan%20Poluri",
"affiliation": {
"@type": "Organization",
"name": "Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee 247667, Uttarakhand, India. Electronic address: krishfbt@iitr.ac.in."
}
},
{
"@type": "Person",
"name": "Nupur Nagar",
"url": "https://questionsmedicales.fr/author/Nupur%20Nagar",
"affiliation": {
"@type": "Organization",
"name": "Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee 247667, Uttarakhand, India."
}
},
{
"@type": "Person",
"name": "Élora Midavaine",
"url": "https://questionsmedicales.fr/author/%C3%89lora%20Midavaine",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Institut de pharmacologie de Sherbrooke, Université de Sherbrooke, 3001, 12e Avenue Nord, Sherbrooke, QC, Canada. elora.midavaine@usherbrooke.ca."
}
},
{
"@type": "Person",
"name": "Philippe Sarret",
"url": "https://questionsmedicales.fr/author/Philippe%20Sarret",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Institut de pharmacologie de Sherbrooke, Université de Sherbrooke, 3001, 12e Avenue Nord, Sherbrooke, QC, Canada."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Understanding Prognosis: Discrepancy in Prognosis Estimates Between Patients With Cirrhosis and their Hepatologists.",
"datePublished": "2022-05-26",
"url": "https://questionsmedicales.fr/article/35643416",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.cgh.2022.04.042"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prognosis of naevoid melanomas.",
"datePublished": "2023-10-09",
"url": "https://questionsmedicales.fr/article/37832354",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.prp.2023.154881"
}
},
{
"@type": "ScholarlyArticle",
"name": "The direct prognosis comparison of",
"datePublished": "2023-06-02",
"url": "https://questionsmedicales.fr/article/37268989",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s40001-023-01140-4"
}
},
{
"@type": "ScholarlyArticle",
"name": "Clinicopathological characteristics and prognosis of medullary thyroid microcarcinoma: a tumor with a similar prognosis to macrocarcinoma.",
"datePublished": "2023-11-28",
"url": "https://questionsmedicales.fr/article/38017592",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s40001-023-01534-4"
}
},
{
"@type": "ScholarlyArticle",
"name": "A retrospective study on the clinical characteristics and prognosis of alopecia totalis and universalis: An update on prognosis.",
"datePublished": "2023-05-19",
"url": "https://questionsmedicales.fr/article/37208851",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/1346-8138.16840"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines et peptides de signalisation intercellulaire",
"item": "https://questionsmedicales.fr/mesh/D036341"
},
{
"@type": "ListItem",
"position": 4,
"name": "Cytokines",
"item": "https://questionsmedicales.fr/mesh/D016207"
},
{
"@type": "ListItem",
"position": 5,
"name": "Chimiokines",
"item": "https://questionsmedicales.fr/mesh/D018925"
},
{
"@type": "ListItem",
"position": 6,
"name": "Chimiokines CC",
"item": "https://questionsmedicales.fr/mesh/D019742"
},
{
"@type": "ListItem",
"position": 7,
"name": "Protéines chimioattractives monocytaires",
"item": "https://questionsmedicales.fr/mesh/D018945"
},
{
"@type": "ListItem",
"position": 8,
"name": "Chimiokine CCL2",
"item": "https://questionsmedicales.fr/mesh/D018932"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Chimiokine CCL2 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Chimiokine CCL2",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-04-30",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Chimiokine CCL2",
"description": "Comment mesurer les niveaux de CCL2 ?\nQuels tests sont utilisés pour évaluer l'inflammation ?\nCCL2 est-il un biomarqueur de maladies ?\nComment CCL2 est-il lié à la maladie cardiovasculaire ?\nPeut-on détecter CCL2 dans le liquide céphalorachidien ?",
"url": "https://questionsmedicales.fr/mesh/D018932?mesh_terms=Prognosis#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Chimiokine CCL2",
"description": "Quels symptômes sont associés à des niveaux élevés de CCL2 ?\nCCL2 est-il lié à des symptômes neurologiques ?\nComment CCL2 affecte-t-il le système immunitaire ?\nDes niveaux de CCL2 peuvent-ils causer de la douleur ?\nCCL2 est-il impliqué dans des maladies respiratoires ?",
"url": "https://questionsmedicales.fr/mesh/D018932?mesh_terms=Prognosis#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Chimiokine CCL2",
"description": "Comment réduire les niveaux de CCL2 ?\nLe stress influence-t-il CCL2 ?\nY a-t-il des aliments qui réduisent CCL2 ?\nL'exercice physique affecte-t-il CCL2 ?\nLa qualité du sommeil influence-t-elle CCL2 ?",
"url": "https://questionsmedicales.fr/mesh/D018932?mesh_terms=Prognosis#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Chimiokine CCL2",
"description": "Quels traitements ciblent CCL2 ?\nCCL2 peut-il être une cible pour des thérapies anticancéreuses ?\nComment les anti-inflammatoires affectent-ils CCL2 ?\nY a-t-il des traitements naturels pour CCL2 ?\nLes corticostéroïdes influencent-ils CCL2 ?",
"url": "https://questionsmedicales.fr/mesh/D018932?mesh_terms=Prognosis#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Chimiokine CCL2",
"description": "Quelles complications sont liées à CCL2 ?\nCCL2 est-il impliqué dans des maladies neurodégénératives ?\nComment CCL2 affecte-t-il le diabète ?\nY a-t-il des risques d'infection liés à CCL2 ?\nCCL2 est-il lié à des troubles auto-immuns ?",
"url": "https://questionsmedicales.fr/mesh/D018932?mesh_terms=Prognosis#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Chimiokine CCL2",
"description": "Quels facteurs augmentent CCL2 ?\nL'âge influence-t-il les niveaux de CCL2 ?\nLes infections chroniques affectent-elles CCL2 ?\nLe régime alimentaire influence-t-il CCL2 ?\nLe manque d'exercice est-il un facteur de risque pour CCL2 ?",
"url": "https://questionsmedicales.fr/mesh/D018932?mesh_terms=Prognosis#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment mesurer les niveaux de CCL2 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les niveaux de CCL2 peuvent être mesurés par des tests ELISA dans le sérum ou les tissus."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'inflammation ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests comme la CRP et la mesure de CCL2 aident à évaluer l'inflammation."
}
},
{
"@type": "Question",
"name": "CCL2 est-il un biomarqueur de maladies ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CCL2 est un biomarqueur potentiel pour des maladies inflammatoires et auto-immunes."
}
},
{
"@type": "Question",
"name": "Comment CCL2 est-il lié à la maladie cardiovasculaire ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés de CCL2 sont associés à l'inflammation dans les maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Peut-on détecter CCL2 dans le liquide céphalorachidien ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CCL2 peut être détecté dans le liquide céphalorachidien, indiquant une inflammation neurologique."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont associés à des niveaux élevés de CCL2 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés de CCL2 peuvent entraîner des symptômes d'inflammation comme douleur et fatigue."
}
},
{
"@type": "Question",
"name": "CCL2 est-il lié à des symptômes neurologiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CCL2 est impliqué dans des symptômes neurologiques dans des maladies comme la sclérose en plaques."
}
},
{
"@type": "Question",
"name": "Comment CCL2 affecte-t-il le système immunitaire ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "CCL2 attire les monocytes et les lymphocytes, influençant la réponse immunitaire."
}
},
{
"@type": "Question",
"name": "Des niveaux de CCL2 peuvent-ils causer de la douleur ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CCL2 peut contribuer à la douleur en favorisant l'inflammation dans les tissus."
}
},
{
"@type": "Question",
"name": "CCL2 est-il impliqué dans des maladies respiratoires ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CCL2 est associé à des maladies respiratoires comme l'asthme et la BPCO."
}
},
{
"@type": "Question",
"name": "Comment réduire les niveaux de CCL2 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Adopter un mode de vie sain, avec une alimentation équilibrée et de l'exercice, peut aider."
}
},
{
"@type": "Question",
"name": "Le stress influence-t-il CCL2 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut augmenter les niveaux de CCL2 et l'inflammation."
}
},
{
"@type": "Question",
"name": "Y a-t-il des aliments qui réduisent CCL2 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des aliments riches en antioxydants, comme les baies, peuvent aider à réduire CCL2."
}
},
{
"@type": "Question",
"name": "L'exercice physique affecte-t-il CCL2 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut diminuer les niveaux de CCL2 et améliorer la santé globale."
}
},
{
"@type": "Question",
"name": "La qualité du sommeil influence-t-elle CCL2 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un sommeil de qualité peut réduire l'inflammation et les niveaux de CCL2 dans le corps."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent CCL2 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs de CCL2 sont en développement pour traiter des maladies inflammatoires."
}
},
{
"@type": "Question",
"name": "CCL2 peut-il être une cible pour des thérapies anticancéreuses ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, cibler CCL2 pourrait aider à réduire l'infiltration tumorale et l'inflammation."
}
},
{
"@type": "Question",
"name": "Comment les anti-inflammatoires affectent-ils CCL2 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les anti-inflammatoires peuvent réduire les niveaux de CCL2 et atténuer l'inflammation."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements naturels pour CCL2 ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines plantes médicinales peuvent moduler les niveaux de CCL2, mais des études sont nécessaires."
}
},
{
"@type": "Question",
"name": "Les corticostéroïdes influencent-ils CCL2 ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les corticostéroïdes peuvent réduire l'expression de CCL2 dans les tissus inflammés."
}
},
{
"@type": "Question",
"name": "Quelles complications sont liées à CCL2 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés de CCL2 peuvent entraîner des complications dans les maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "CCL2 est-il impliqué dans des maladies neurodégénératives ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CCL2 est associé à des complications dans des maladies comme Alzheimer et Parkinson."
}
},
{
"@type": "Question",
"name": "Comment CCL2 affecte-t-il le diabète ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "CCL2 peut contribuer à l'inflammation et aux complications associées au diabète."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques d'infection liés à CCL2 ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés de CCL2 peuvent augmenter le risque d'infections en favorisant l'inflammation."
}
},
{
"@type": "Question",
"name": "CCL2 est-il lié à des troubles auto-immuns ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CCL2 est impliqué dans des complications de troubles auto-immuns comme la polyarthrite."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent CCL2 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le tabagisme, l'obésité et le stress sont des facteurs de risque augmentant CCL2."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il les niveaux de CCL2 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les niveaux de CCL2 tendent à augmenter avec l'âge, contribuant à l'inflammation."
}
},
{
"@type": "Question",
"name": "Les infections chroniques affectent-elles CCL2 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les infections chroniques peuvent augmenter les niveaux de CCL2 dans le corps."
}
},
{
"@type": "Question",
"name": "Le régime alimentaire influence-t-il CCL2 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un régime riche en graisses saturées peut augmenter les niveaux de CCL2 et l'inflammation."
}
},
{
"@type": "Question",
"name": "Le manque d'exercice est-il un facteur de risque pour CCL2 ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le manque d'exercice peut contribuer à des niveaux élevés de CCL2 et à l'inflammation."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 20/02/2025
Contenu vérifié selon les dernières recommandations médicales
4 publications dans cette catégorie
Affiliations :
Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee 247667, Uttarakhand, India.
Publications dans "Chimiokine CCL2" :
4 publications dans cette catégorie
Affiliations :
Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee 247667, Uttarakhand, India. Electronic address: krishfbt@iitr.ac.in.
Publications dans "Chimiokine CCL2" :
3 publications dans cette catégorie
Affiliations :
Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee 247667, Uttarakhand, India.
Publications dans "Chimiokine CCL2" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Institut de pharmacologie de Sherbrooke, Université de Sherbrooke, 3001, 12e Avenue Nord, Sherbrooke, QC, Canada. elora.midavaine@usherbrooke.ca.
Centre de recherche du Centre hospitalier universitaire de Sherbrooke, CIUSSS de l'Estrie - CHUS, Sherbrooke, QC, Canada. elora.midavaine@usherbrooke.ca.
Publications dans "Chimiokine CCL2" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Institut de pharmacologie de Sherbrooke, Université de Sherbrooke, 3001, 12e Avenue Nord, Sherbrooke, QC, Canada.
Centre de recherche du Centre hospitalier universitaire de Sherbrooke, CIUSSS de l'Estrie - CHUS, Sherbrooke, QC, Canada.
Publications dans "Chimiokine CCL2" :
2 publications dans cette catégorie
Affiliations :
Centre of Biomedical Research, SGPGIMS Campus, Lucknow 226014, Uttar Pradesh, India.
Publications dans "Chimiokine CCL2" :
2 publications dans cette catégorie
Affiliations :
Department of Biosciences and Bioengineering, Indian Institute of Technology Roorkee, Roorkee 247667, Uttarakhand, India.
Publications dans "Chimiokine CCL2" :
2 publications dans cette catégorie
Affiliations :
Institute of Pharmaceutical Sciences, University of Graz, 8010 Graz, Austria.
Publications dans "Chimiokine CCL2" :
2 publications dans cette catégorie
Affiliations :
Institute of Pharmaceutical Sciences, University of Graz, 8010 Graz, Austria.
Publications dans "Chimiokine CCL2" :
2 publications dans cette catégorie
Affiliations :
Department of Rehabilitation Medicine, Affiliated Hospital of Nantong University, 226001, Nantong, Jiangsu Province, China.
School of Medicine, Nantong University, 226001, Nantong, Jiangsu Province, China.
Publications dans "Chimiokine CCL2" :
2 publications dans cette catégorie
Affiliations :
Istituti Clinici Scientifici Maugeri IRCCS, Unit of Internal Medicine and Endocrinology, Laboratory for Endocrine Disruptors, Pavia, Italy.
Publications dans "Chimiokine CCL2" :
2 publications dans cette catégorie
Affiliations :
Istituti Clinici Scientifici Maugeri IRCCS, Unit of Internal Medicine and Endocrinology, Laboratory for Endocrine Disruptors, Pavia, Italy.
Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.
Publications dans "Chimiokine CCL2" :
2 publications dans cette catégorie
Affiliations :
Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy.
Publications dans "Chimiokine CCL2" :
2 publications dans cette catégorie
Affiliations :
Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy.
Publications dans "Chimiokine CCL2" :
2 publications dans cette catégorie
Affiliations :
Department of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa, 56126 Pisa, Italy.
Publications dans "Chimiokine CCL2" :
2 publications dans cette catégorie
Affiliations :
Department of Transplantation Medicine, Nephrology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland. jgozdowska@wum.edu.pl
Publications dans "Chimiokine CCL2" :
2 publications dans cette catégorie
Affiliations :
Department of General and Transplantation Surgery, Medical University of Warsaw, Warsaw, Poland
Publications dans "Chimiokine CCL2" :
2 publications dans cette catégorie
Affiliations :
Department of Transplantation Medicine, Nephrology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland
Publications dans "Chimiokine CCL2" :
2 publications dans cette catégorie
Affiliations :
College of Medicine and Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates.
Publications dans "Chimiokine CCL2" :
2 publications dans cette catégorie
Affiliations :
College of Medicine and Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates.
Publications dans "Chimiokine CCL2" :
Patients require a clear understanding of their prognosis to make informed decisions about their care. The aim of this study was to compare the perceptions of prognosis and transplant candidacy betwee...
Patients with cirrhosis and their hepatologists were prospectively recruited at an urban liver transplant center. Patients and hepatologists were asked about transplant candidacy and about how many ye...
Seventy patients and 6 hepatologists were enrolled in the study. Patients were predominantly male (61.4%) and white (68.6%), with a mean MELD-Na score of 19 ± 9. There was no-slight agreement between ...
Patients with cirrhosis are more optimistic and less accurate in their predictions of survival compared with hepatologists, although they are more realistic about their transplant candidacy. Aligning ...
There appear to be several variants of naevoid melanoma suspected as having different outcomes, but follow-up studies have been few. We aimed to assess the prognosis of naevoid melanomas in a multi-ce...
From histopathology records we ascertained patients in the UK, Australia and Italy diagnosed with maturing naevoid melanoma (n = 65; 14; 7 respectively) and nodular/papillomatous naevoid melanoma (12;...
Among UK patients, there was a non-significantly lower risk of melanoma death in maturing naevoid vs SSM, including after accounting for competing causes of death (SHR 0.40, 95% confidence interval (C...
There was no significant difference in risk of death from melanomas with naevoid features, and SSM. Nodular/ papillomatous naevoid melanoma patients did not carry higher risk of death than SSM patient...
This study aims to compare the clinical outcomes after performing radical prostatectomy (RP) or low-dose-rate brachytherapy (LDR) for patients with intermediate-risk prostate cancer (IRPC)....
We performed a retrospective analysis on 361 IRPC patients who underwent treatment in Peking Union Medical College Hospital from January 2014 to August 2021, of which 160 underwent RP and 201 underwen...
Median follow-up was 54 months for RP and 69 months for LDR. According to log-rank test, the differences of 5-year bRFS (70.2% vs 83.2%, P = 0.003) and 8-year bRFS (63.1% vs 68.9%, P < 0.001) between ...
LDR is a reasonable treatment option for IRPC patients, yielding improved bRFS and equivalent rates of cRFS, CSS and OS when compared with RP....
Tumor size plays an important role in the staging and treatment of thyroid carcinoma. A tumor with a maximum diameter of 1 cm or less is referred to as microcarcinoma. It is unclear if the clinicopath...
The patients with medullary thyroid carcinoma underwent radical operation at our hospital between December 2000 and January 2022 were retrospectively studied. A database was established for this study...
A total of 198 patients were included. Of them, 56 and 142 with MTMC and macrocarcinoma, respectively. Few patients in the MTMC group had lateral lymph node metastasis. One hundred and seventy-eight (...
Patients with MTMC have a lower risk of lateral lymph node metastasis and better disease-free survival than those with macrocarcinoma. However, there was no significant difference in the overall survi...
Alopecia totalis (AT) and alopecia universalis (AU) is known to have a poor prognosis with high relapse rate, and treatment failure is observed in most patients, regardless of the type of therapy. Alt...
Immune and stromal cells contribute to glioma progression by infiltrating the tumor microenvironment. We used clinical characteristics, RNA sequencing data and the ESTIMATE algorithm to obtain stromal...
Prognostic studies are investigations to estimate the risk or probability of future outcomes in people with established disease. Ideally based on cohort studies where it is established: the time of on...
Cholangiocarcinoma (CHOL) is a malignant tumor that originates in the extrahepatic bile duct and can extend from the hilar region to the lower end of the common bile duct. The prognosis of CHOL patien...
The TCGA-CHOL dataset was applied to obtain and analyze the coexpression of 1281 m...
Kaplan-Meier analysis indicated poor overall survival (OS) for the high-risk group. Two Gene Expression Omnibus (GEO) datasets (GSE89748 and GSE107943) were used to validate the risk model. The result...
Our findings suggest that this model can be a prognostic indicator for CHOL patients....
Head and neck squamous cell carcinoma (HNSCC), the most common head and neck cancer, is highly aggressive and heterogeneous, resulting in variable prognoses and immunotherapeutic outcomes. Natural kil...
In this study, NRGs were used to classify HNSCC from the TCGA-HNSCC and GEO cohorts. The genes were evaluated using univariate cox regression analysis based on the differential analysis of normal and ...
With the TCGA-HNSCC data, we established a nomogram based on the 17-NRGs signature and a variety of clinicopathological characteristics. The low-risk group exhibited a better effect when it came to im...
17-NRGs signature and nomograms demonstrate excellent predictive performance and offer new perspectives for assessing pre-immune efficacy, which will facilitate future precision immuno-oncology resear...
Genetics plays a significant role in determining an individual's susceptibility to dental diseases, the response to dental treatments, and the overall prognosis of dental interventions. Here, the auth...